Endocrine Abstracts

Introduction: Several publications now demonstrate that growth hormone therapy in replacement doses does not increase the future risk of recurrence in brain tumours. However, there is less certainty about the best and safest time to start growth hormone (GH) therapy after completion of primary treatment with recent guidance suggesting that a delay of 1 year is appropriate. We plan to determine if the timing of GH initiation is related to the likelihood of tumour progression. <...

Background: Adamantinomatous craniopharyngiomas (ACPs) are rare, benign, epithelial tumours of the sellar-suprasellar region. Craniopharyngiomas cause considerable morbidity and mortality due to local invasion and treatment-related damage to surrounding structures, including the hypothalamus and pituitary gland, leading to hypopituitarism and diabetes insipidus (DI). Trametinib is a highly selective mitogen-activated protein kinase (MEK) inhibitor, which has been recently used...

Background: Neuroblastoma investigations and treatments are associated with thyroid dysfunction. This study aims to identify the consequences of different neuroblastoma investigations and treatments on the thyroid status of patients.Methods: This is a retrospective cohort study of neuroblastoma patients at a tertiary paediatric endocrinology/oncology centre. Electronic records were reviewed for previous treatments (chemotherapy, surgery, radiotherapy, an...

Background & Objective: Pseudohypoparathyroidism (PHP), a heterogeneous condition, classically causes parathyroid hormone (PTH) resistance. PHP1a is caused by heterozygous inactivating mutations on the maternally derived GNAS allele. PHP1b results from methylation defects at the GNAS imprinted gene cluster, which are either sporadic, or familial, normally associated with maternally inherited intragenic STX16 deletions. We investigated the presentation, phenotype, ...